VeraBank N.A. Reduces Stock Position in Danaher Co. (NYSE:DHR)

VeraBank N.A. reduced its holdings in Danaher Co. (NYSE:DHRFree Report) by 2.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,571 shares of the conglomerate’s stock after selling 240 shares during the period. Danaher makes up 0.7% of VeraBank N.A.’s portfolio, making the stock its 29th largest holding. VeraBank N.A.’s holdings in Danaher were worth $2,390,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares in the last quarter. Capital International Investors lifted its holdings in Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares in the last quarter. Norges Bank bought a new stake in Danaher during the 4th quarter valued at about $1,752,382,000. Finally, Franklin Resources Inc. lifted its holdings in Danaher by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock valued at $1,531,510,000 after buying an additional 395,498 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR traded up $2.41 during trading hours on Wednesday, hitting $242.20. The stock had a trading volume of 2,090,825 shares, compared to its average volume of 2,861,986. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a 50-day moving average price of $255.06 and a 200 day moving average price of $247.32. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The firm has a market capitalization of $179.40 billion, a price-to-earnings ratio of 41.05, a PEG ratio of 3.68 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the business posted $2.36 EPS. The business’s revenue was down 2.6% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Joakim Weidemanis sold 22,433 shares of the stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $250.46, for a total value of $5,618,569.18. Following the completion of the sale, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 148,783 shares of company stock worth $37,536,717. Company insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. TD Cowen boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Evercore ISI reduced their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.

Check Out Our Latest Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.